

## CLAIMS:

1. An isolated polypeptide comprising a sequence selected from the group consisting of SEQ ID NO: 11-20, 30-38, 47-53 and 59-61.
2. An isolated polypeptide comprising a sequence selected from the group consisting of:
  - (a) sequences having at least 60% identity to a sequence provided in SEQ ID NO: 11-20, 30-38, 47-53 and 59-61 as determined using the computer algorithm BLASTP;
  - (b) sequences having at least 75% identity to a sequence provided in SEQ ID NO: 11-20, 30-38, 47-53 and 59-61 as determined using the computer algorithm BLASTP; and
  - (d) sequences having at least 90% identity to a sequence provided in SEQ ID NO: 11-20, 30-38, 47-53 and 59-61 as determined using the computer algorithm BLASTP.
3. An isolated polynucleotide that encodes a polypeptide according to any one of claims 1 and 2.
4. An isolated polynucleotide of claim 3, wherein the polynucleotide comprises a sequence selected from the group consisting of sequences provided in SEQ ID NO: 1-10, 21-29, 39-46 and 58.
5. An isolated polynucleotide comprising a sequence selected from the group consisting of:
  - (a) complements of a sequence provided in SEQ ID NO: 1-10, 21-29, 39-46 and 59;
  - (b) reverse complements of a sequence provided in SEQ ID NO: 1-10, 21-29, 39-46 and 59;
  - (c) reverse sequences of a sequence provided in SEQ ID NO: 1-10, 21-29, 39-46 and 59;
  - (d) sequences having at least 60% identity to a sequence provided in SEQ ID NO: 1-10, 21-29, 39-46 and 59 as determined using the computer algorithm BLASTN;
  - (e) sequences having at least 75% identity to a sequence provided in SEQ ID NO: 1-10, 21-29, 39-46 and 59 as determined using the computer algorithm BLASTN; and
  - (g) sequences having at least 90% identity to a sequence provided in SEQ ID NO: 1-10, 21-29, 39-46 and 59 as determined using the computer algorithm BLASTN.

6. An isolated polynucleotide comprising a sequence selected from the group consisting of:  
(a) sequences that are a 200-mer of an isolated polynucleotide according to any one of claims 3, 4 and 5; (b) sequences that are a 100-mer of an isolated polynucleotide according to any one of claims 3, 4 and 5; and (c) sequences that are a 40-mer of an isolated polynucleotide according to any one of claims 3, 4 and 5.
7. An expression vector comprising an isolated polynucleotide according to any one of claims 3-6.
8. A host cell transformed with an expression vector according to claim 7.
9. An isolated polypeptide comprising at least a functional portion of a polypeptide having an amino acid sequence selected from the group consisting of sequences provided in SEQ ID NO: 11-20, 30-38, 47-53 and 59.
10. An isolated polypeptide according to claim 9, wherein the functional portion is selected from the group consisting of: SEQ ID NO: 60 and 61.
11. A composition comprising an isolated polypeptide according to any one of claims 1, 2 and 9.
12. A composition comprising an isolated polynucleotide according to any one of claims 3-6.
13. A method for the treatment of an inflammatory disorder in a patient, comprising administering to the patient a composition according to any one of claims 11 and 12.
14. A method for modulating the growth of blood vessels in a patient, comprising administering to the patient a composition according to any one of claims 11 and 12.
15. A method for the treatment of a disorder of the immune system in patient, comprising administering to the patient a composition according to any one of claims 11 and 12.
16. A method for the treatment of cancer in a patient, comprising administering to the patient a composition according to any one of claims 11 and 12, wherein the cancer is selected from the group consisting of epithelial, lymphoid, myeloid, stromal and neuronal cancers.
17. A method for the treatment of a tumour necrosis factor-mediated disorder in a patient, comprising administering to the patient a composition comprising an isolated polypeptide, the polypeptide comprising an amino acid sequence selected from the group consisting of:
  - (a) a sequence of SEQ ID NO: 13;

- (b) sequences having at least 60% identity to the sequence of SEQ ID NO: 13 as determined using the computer algorithm BLASTP;
  - (c) sequences having at least 75% identity to the sequence of SEQ ID NO: 13 as determined using the computer algorithm BLASTP; and
  - (d) sequences having at least 90% identity to the sequence of SEQ ID NO: 13 as determined using the computer algorithm BLASTP.
18. The method of claim 17, wherein the tumour necrosis factor-mediated disorder is selected from the group consisting of arthritis, inflammatory bowel disease and cardiac failure.
19. A method for the treatment of a viral disorder in a patient, comprising administering to the patient a composition according to any one of claims 11 and 12.
20. The method of claim 19, wherein the viral disorder is HIV-infection.
21. A method for the treatment of a fibroblast growth factor-mediated disorder in a patient, comprising administering to the patient a composition comprising an isolated polypeptide, the polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) a sequence provided in SEQ ID NO: 30-33;
  - (b) sequences having at least 60% identity to a sequence provided in SEQ ID NO: 30-33 as determined using the computer algorithm BLASTP;
  - (c) sequences having at least 75% identity to a sequence provided in SEQ ID NO: 30-33 as determined using the computer algorithm BLASTP; and
  - (d) sequences having at least 90% identity to a sequence provided in SEQ ID NO: 30-33 as determined using the computer algorithm BLASTP.
22. A method for enhancing an immune response in a patient, comprising administering to the patient a composition comprising an isolated polypeptide, the polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) a sequence provided in SEQ ID NO: 31-33;
  - (b) sequences having at least 60% identity to a sequence provided in SEQ ID NO: 31-33 as determined using the computer algorithm BLASTP;
  - (c) sequences having at least 75% identity to a sequence provided in SEQ ID NO: 31-33 as determined using the computer algorithm BLASTP; and

- (d) sequences having at least 90% identity to a sequence provided in SEQ ID NO: 31-33 as determined using the computer algorithm BLASTP.